Silence Therapeutics Announces Positive Divesiran Trial Results
Ticker: SLNCF · Form: 6-K · Filed: Jun 27, 2024 · CIK: 1479615
| Field | Detail |
|---|---|
| Company | Silence Therapeutics PLC (SLNCF) |
| Form Type | 6-K |
| Filed Date | Jun 27, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial-results, biotech, drug-development
TL;DR
Silence Therapeutics (SLN) drops positive Phase 1 data for PV drug divesiran, looks promising.
AI Summary
On June 27, 2024, Silence Therapeutics plc announced positive initial results from its SANRECO Phase 1 repeat dose clinical trial for divesiran (SLN124). Divesiran is a siRNA targeting TMPRSS6 and is being tested in patients with polycythemia vera (PV). The press release detailing these results is attached as Exhibit 99.1 to this Form 6-K filing.
Why It Matters
Positive clinical trial results for divesiran could advance the treatment of polycythemia vera, a serious blood disorder, potentially offering a new therapeutic option for patients.
Risk Assessment
Risk Level: medium — Clinical trial results are inherently uncertain, and further studies are needed to confirm efficacy and safety.
Key Players & Entities
- Silence Therapeutics plc (company) — Registrant
- June 27, 2024 (date) — Date of press release
- SANRECO (trial) — Clinical trial name
- Phase 1 (trial_phase) — Clinical trial phase
- divesiran (SLN124) (drug) — Investigational drug
- siRNA (technology) — Drug mechanism
- TMPRSS6 (gene) — Drug target
- polycythemia vera (PV) (disease) — Patient condition
- Exhibit 99.1 (document) — Attached press release
FAQ
What specific positive results were announced for divesiran in the SANRECO trial?
The filing states that positive initial results were announced, but the specific details are contained within Exhibit 99.1, which is a press release.
What is the target indication for divesiran (SLN124)?
Divesiran (SLN124) is being tested in patients with polycythemia vera (PV).
What is the mechanism of action for divesiran?
Divesiran is a siRNA (short referencing RNA) that targets TMPRSS6.
When was the press release announcing these results issued?
The press release was issued on June 27, 2024.
Which clinical trial is reporting these initial results?
The initial results are from the ongoing SANRECO Phase 1 repeat dose clinical trial.
Filing Stats: 1,378 words · 6 min read · ~5 pages · Grade level 15.6 · Accepted 2024-06-27 07:40:52
Filing Documents
- d651124d6k.htm (6-K) — 20KB
- d651124dex991.htm (EX-99.1) — 19KB
- d651124dex992.htm (EX-99.2) — 19KB
- g651124ex99_2p10g1.jpg (GRAPHIC) — 425KB
- g651124ex99_2p11g1.jpg (GRAPHIC) — 342KB
- g651124ex99_2p12g1.jpg (GRAPHIC) — 204KB
- g651124ex99_2p13g1.jpg (GRAPHIC) — 218KB
- g651124ex99_2p14g1.jpg (GRAPHIC) — 189KB
- g651124ex99_2p15g1.jpg (GRAPHIC) — 193KB
- g651124ex99_2p16g1.jpg (GRAPHIC) — 199KB
- g651124ex99_2p17g1.jpg (GRAPHIC) — 175KB
- g651124ex99_2p18g1.jpg (GRAPHIC) — 191KB
- g651124ex99_2p19g1.jpg (GRAPHIC) — 349KB
- g651124ex99_2p1g1.jpg (GRAPHIC) — 182KB
- g651124ex99_2p20g1.jpg (GRAPHIC) — 334KB
- g651124ex99_2p21g1.jpg (GRAPHIC) — 113KB
- g651124ex99_2p22g1.jpg (GRAPHIC) — 273KB
- g651124ex99_2p2g1.jpg (GRAPHIC) — 699KB
- g651124ex99_2p3g1.jpg (GRAPHIC) — 336KB
- g651124ex99_2p4g1.jpg (GRAPHIC) — 146KB
- g651124ex99_2p5g1.jpg (GRAPHIC) — 478KB
- g651124ex99_2p6g1.jpg (GRAPHIC) — 367KB
- g651124ex99_2p7g1.jpg (GRAPHIC) — 417KB
- g651124ex99_2p8g1.jpg (GRAPHIC) — 311KB
- g651124ex99_2p9g1.jpg (GRAPHIC) — 225KB
- g651124g0627043059639.jpg (GRAPHIC) — 3KB
- 0001193125-24-169739.txt ( ) — 8833KB
Forward-Looking Statements
Forward-Looking Statements This Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this Report other than statements of historical facts are forward-looking statements. These statements may be identified by words such as aims, anticipates, believes, could, estimates, expects, forecasts, goal, intends, may, plans, possible, potential, seeks, will and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this Report include, but are not limited to, statements regarding: the Companys clinical development activities and timelines for divesiran including the expected timing for reporting further data from the SANRECO trial; the timing and future occurrence of other clinical and clinical activities including proposed clinical trial enrollment and the Companys plans and timing to advance divesiran into Phase 2; expected clinical benefits of divesiran and the potential to produce clinically meaningful outcomes in PV patients; and the Companys plans to submit additional data from the SANRECO trial for publication at a future conference. These forward-looking statements are based on the Companys expectations and assumptions as of the date of this Report. Each of these forward-looking cause differences between current expectations and actual results, including: preliminary or topline results are based on a preliminary analysis of key efficacy and safety data; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results o